From the Neurology and Stroke Unit (M. Romoli, M.L.), Nuclear Medicine (F.M., V.M.), Diagnostic Neuroradiology Unit (P.C.), and Interventional Neuroradiology Unit (M. Ruggiero), Bufalini Hospital, AUSL Romagna, Cesena; Cerebrovascular Unit (G.M., N.R., I.C., G.B., A.B., B.S.) and Neuroradiology Unit (M.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta; and Nuclear Medicine Department (L.T., A.C.), Ospedale San Paolo, Milan, Italy.
Neurology. 2024 Aug 27;103(4):e209719. doi: 10.1212/WNL.0000000000209719. Epub 2024 Jul 31.
Cerebral amyloid angiopathy (CAA)-related features on neuroimaging often coexist with signs of arteriolosclerosis-small vessel disease on neuroimaging in people with intracranial hemorrhage (ICH). This study aimed at defining the value of amyloid pathology detected by flutemetamol PET in reclassification and stratification of risk of bleeding in people with mixed CAA-arteriolosclerosis features.
We included consecutive patients admitted to 2 institutions (2018-2023) with spontaneous symptomatic ICH, subarachnoid hemorrhage (SAH), transient focal neurologic episodes (TFNE), or cognitive impairment and MRI showing CAA hallmarks. All patients underwent brain magnetic resonance imaging (MRI) with susceptibility weighted imaging and flutemetamol PET imaging and were followed up for at least 1 year. We compared cases with CAA and arteriolosclerosis + CAA features and defined long-term outcomes (composite outcome including death, ICH, ischemic stroke, SAH, TFNE) depending on PET status (CAA/amyloid pathology vs arteriolosclerosis-predominant groups).
Among 47 patients, according to PET and MRI imaging, 38 patients were reclassified in the CAA/amyloid pathology group and 9 in the arteriolosclerosis-predominant group, with similar cardiovascular risk factors but a significantly higher lobar microbleed burden for the former group. The CAA/amyloid pathology group had higher rates of composite outcome (43.9 vs 11.1 events per 100 patient-year; = 0.039) and ICH (36.5 vs 5.6 events per 100 patient-years; = 0.04) compared with the arteriolosclerosis-predominant group.
Flutemetamol PET imaging can help in reclassification of mixed arteriolosclerosis + CAA into CAA/amyloid pathology and arteriolosclerosis-predominant, with implications on long-term risk of recurrent events.
This study provides Class IV evidence that flutemetamol PET can distinguish between CAA + arteriolosclerosis and arteriolosclerosis-predominant pathology.
在颅内出血(ICH)患者中,脑淀粉样血管病(CAA)相关影像学特征常与小血管疾病的影像学表现并存。本研究旨在定义淀粉样蛋白病理学在伴有混合 CAA-小血管疾病特征的患者中出血风险再分类和分层中的价值。
我们纳入了 2018 年至 2023 年期间在 2 家机构(2018-2023)因自发性症状性 ICH、蛛网膜下腔出血(SAH)、短暂性局灶性神经事件(TFNE)或认知障碍且 MRI 显示 CAA 特征而入院的连续患者。所有患者均接受了脑磁共振成像(MRI)检查,包括磁敏感加权成像和 flutemetamol PET 成像,并进行了至少 1 年的随访。我们比较了 CAA 和小血管疾病+ CAA 特征的病例,并根据 PET 状态(CAA/淀粉样蛋白病理学与小血管疾病为主的组)定义了长期结局(包括死亡、ICH、缺血性卒、SAH、TFNE 的复合结局)。
在 47 例患者中,根据 PET 和 MRI 成像,38 例患者被重新分类为 CAA/淀粉样蛋白病理学组,9 例患者被分类为小血管疾病为主的组,前者组的心血管危险因素相似,但皮质下微出血负担明显更高。与小血管疾病为主的组相比,CAA/淀粉样蛋白病理学组的复合结局发生率(43.9/100 患者年 vs 11.1/100 患者年; = 0.039)和 ICH 发生率(36.5/100 患者年 vs 5.6/100 患者年; = 0.04)更高。
flutemetamol PET 成像有助于将混合小血管疾病+ CAA 重新分类为 CAA/淀粉样蛋白病理学和小血管疾病为主的组,这对复发性事件的长期风险有影响。
本研究提供了 IV 级证据,证明 flutemetamol PET 可以区分 CAA+小血管疾病和小血管疾病为主的病理学。